|
|
Vaccine Detail
|
rMA15-ΔE vaccine |
| Vaccine Information |
- Vaccine Name: rMA15-ΔE vaccine
- Target Pathogen: SARS-CoV
- Target Disease: Severe Acute Respiratory Syndrome (SARS)
- Type: Live, attenuated vaccine
- Status: Research
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: mouse
- Antigen: virulent mouse-adapted SARS-CoV with E-deletion (rMA15-ΔE) (Fett et al., 2013)
- envelope protein (E) gene of SARS-CoV
gene engineering:
- Type: Gene mutation
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
- Description: recombinant MA15 virulent mouse-adapted SARS-CoV (MA15) background of E-deleted vaccine candidate (rMA15-ΔE) (Fett et al., 2013)
|
| Host Response |
|
Mouse Response
- Host Strain: Balb/c
- Immune Response: Induced neutralizing antibodies, Produced optimal levels of CD4 and CD8 T cells (Fett et al., 2013)
- Side Effects: Minor peribronchial and perivascular infiltration in aged (18-month-old) mice (Fett et al., 2013)
- Challenge Protocol: Mice were challenged with 10^5 PFU of MA15 at day 21 after immunization. (Fett et al., 2013)
- Efficacy: Protected (Fett et al., 2013)
|
| References |
Fett et al., 2013: Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. Journal of virology. 2013; 87(12); 6551-6559. [PubMed: 23576515].
|
|
